Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07888829). This is a study registration, not published results. Lead sponsor: University of Health Sciences Lahore. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 52 participants (ESTIMATED). Conditions: Neonatal Sepsis, Neutropenia. Interventions: BIOLOGICAL: Granulocyte-colony stimulating factor (G-CSF); BIOLOGICAL: Standard Sepsis Management. Primary outcome measures: Mortality , From enrollment until discharge or death, within the first 28 days of life. Brief summary: This study will evaluate whether adding G-CSF to standard treatment improves outcomes in newborns (0-28 days) with sepsis and neutropenia. It will compare survival, recovery of neutrophil counts, hospital stay, infections, and adverse effects between babies receiving G-CSF and standard treatment alone.